Biogen (BIIB) Free Cash Flow (2009 - 2026)

Biogen's Free Cash Flow history runs 18 years deep, the most recent figure standing at $408.0 million for Q2 2026.

• In Q2 2026, Free Cash Flow rose 203.8% year-over-year to $408.0 million; the TTM figure through Jun 2026 stood at $2.7 billion (up 36.28% YoY), while the FY2025 annual figure was $2.1 billion, down 24.65% from the prior year.
• Free Cash Flow for Q2 2026 stood at $408.0 million, down from $594.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $1.2 billion in Q3 2025, with the low at -$261.4 million in Q4 2022.
• The 5-year median for Free Cash Flow is $487.6 million (2024), against an average of $455.0 million.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow slumped 133.23% in 2022, then soared 1469.26% in 2024.
• Biogen's Free Cash Flow stood at -$261.4 million in 2022, then soared by 79.84% to -$52.7 million in 2023, then jumped by 1469.26% to $721.6 million in 2024, then sank by 35.14% to $468.0 million in 2025, then fell by 12.82% to $408.0 million in 2026.
• Business Quant data shows BIIB's Free Cash Flow at $408.0 million in Q2 2026, $594.3 million in Q1 2026, and $468.0 million in Q4 2025.